25th Sep 2009 16:42
Friday 25 September 2009
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Exercise of Warrants
Allergy Therapeutics (AIM: AGY) announces that on 24 September 2009, Azure Ventures Limited partially exercised the warrant to subscribe for ordinary shares in the Company issued to it on 1 July 2009. The exercise was in respect of 16,273,393 new ordinary shares (the "Ordinary Shares") at an exercise price of 12.29 pence per share for a total consideration of GBP2.0M.
Application has been made for the admission to trading on AIM ("Admission") of 16,273,393 Ordinary Shares at nominal value with Admission expected to take place on 1 October 2009, this now completes Azure's warrant rights.
Azure Ventures Limited will be interested in 132,940,059 Ordinary Shares, representing 45.41 per cent. of the Company's total voting rights after Admission.
After Admission, the Company's issued share capital will consist of 292,771,944 Ordinary Shares.
For further information
|
Allergy Therapeutics |
+44 (0) 1903 845 820 |
|
Ian Postlethwaite, Finance Director |
|
|
www.allergytherapeutics.com |
|
|
Nomura Code Securities |
+44 (0) 207 776 1200 |
|
Juliet Thompson/ Clare Terlouw |
|
|
Financial Dynamics |
+44 (0) 207 831 3113 |
|
Ben Brewerton/ Susan Quigley |
Related Shares:
Allergy Thera.